Lymphoma Treatment Market to Reach USD 13.11 Billion by 2026; Adoption of Advanced Therapeutics to Propel Market

The global lymphoma treatment market size is predicted to reach USD 13.11 billion by 2026. The growing rate of lymphomas has led to the necessity for early diagnosis, which, in turn, will encourage the growth of market for lymphoma treatment, during the forecast period. In addition, the rising cases of refractory diseases such as cancer will spur opportunities for the market in the forthcoming years, mentioned in a report, titled “Lymphoma Treatment Market Size, Share & Industry Analysis, By Therapy (Immunotherapy, Targeted Therapy, Chemotherapy, and Others), By Disease Type (Non-Hodgkin Lymphoma, and Hodgkin Lymphoma), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies & Drug Stores, and Online Pharmacies), and Regional Forecast, 2019-2026” the market size stood at USD 6.94 billion in 2018 and is predicted to exhibit a CAGR of 8.3% between 2019 to 2026.

Approval of Kymriah and Yescarta by European Commission to Speed up Growth Process

The approval of two chimeric antigen receptor T-cell (CAR-T) therapies, Novartis’ Kymriah and Gilead’s Yescarta by European Commission for the treatment of patients within the EU.  The approval involves the marketing and distribution of both the therapies across the European market. Kymriah will be used for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy. Whereas, Yescarta will be used the latter indication and for the treatment of primary mediastinal large B-cell lymphoma, after two or more lines of systemic therapy. The approval of both the therapies for the European market will contribute positively to the lymphoma treatment market trends owing to the results achieved by the clinical trials. For instance, Yescarta achieved 51% complete response rate in patients with refractory aggressive non-Hodgkin lymphoma.

To get a detailed report summary and research scope of this market, click here:

https://www.fortunebusinessinsights.com/industry-reports/lymphoma-treatment-market-100262

Limited Access to Advanced Therapeutics will Restrict Growth

The limited adoption to therapeutics in emerging countries of Asia Pacific is predicted to hamper the growth of the market. The increasing prevalence of blood cancers along with lack of adoption of expensive therapeutics in developing countries will dwindle the growth of the market during the forecast period. The limited number of patients undergoing treatment owing to the lack of access to advanced treatment will restrict the growth of the market during the forecast period. In addition, lack of awareness along with lack of appropriate payment plans in the rural areas will dampen the growth of the market in the forthcoming years.

Clinical Trials by Leading Players to Enhance Market Competition

The leading players present in the market are concentrating on clinical trials to strengthen their market position. The focus on building diversified portfolio of cancer therapeutics by some leading player will consolidate market in the foreseeable future. Several major market players such as Takeda Pharmaceutical Company Limited and Gilead Sciences, Inc. with its subsidiary Kite Pharma, Inc. will hold major share in the market during the forecast period owing to the its strong product portfolio. Novartis AG, and Bristol Myers Squibb Company also positioned themselves in the market with a wide range of immunotherapy to targeted therapy.

The Report Lists the Key Companies in the Lymphoma Treatment Market

• Takeda Pharmaceutical Company Limited
• AstraZeneca
• Bayer AG
• Novartis AG
• Kite Pharma, Inc. / Gilead Sciences, Inc.
• Spectrum Pharmaceuticals, Inc.
• Teva Pharmaceutical Industries Ltd.
• Bristol Myers Squibb Company
• Janssen Pharmaceuticals, Inc.

Further Report Findings:

• Regional Analysis: The market in North America stood at USD 3.33 billion in 2018. The growth in the region is attributed to the growing treatment options for cancer patient along. The developed infrastructure along with rising adoption of advanced therapeutics will support growth in North America.
• Leading Segments: The targeted therapy segment accounted for 36.2% in 2018 and is predicted to be one of the leading segments in the forthcoming years owing to a large number of product offerings along with the accuracy of these therapies in the targeting of the cancer.

This Market is Segmented into: